Answers are grounded in this paper and cite their sources.
The association between ranolazine use and the outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has not been investigated. We examined 11,491 CTO PCIs (11,478 patients) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS CTO registry. During the study period, 1,720 (15%) patients undergoing CTO PCI were using ranolazine on baseline. Patients receiving ranolazine had a higher prevalence of diabetes, hypertension, dyslipidemia, family history of coronary artery disease, prior history of PCI, coronary artery bypass graft surgery, cerebrovascular and peripheral arterial disease. They had higher J-CTO (2.85 vs 2.31; p<0.001) and PROGRESS-CTO (1.45 vs 1.21; p<0.001) scores, longer lesion length and higher prevalence of proximal cap ambiguity, blunt/no stump, moderate to severe calcification and proximal tortuosity. Their procedure (139.00 vs 108.00 min; p<0.001) and fluoroscopy (53.00 vs 40.00 min; p<0.001) times were longer. Technical (83.7% vs 87.8%; p<0.001) and procedural (81.4% vs 86.6%; p<0.001) success were lower in patients using ranolazine, while the incidence of major adverse cardiovascular events (MACE) was higher (3.2% vs 1.8%; p<0.001) due to higher in-hospital mortality (0.8% vs 0.4%; p=0.051), acute myocardial infarction (0.9% vs 0.4%; p=0.006), repeat PCI (0.5% vs 0.1%; p=0.006), stroke (0.4% vs 0.1%; p=0.008) and perforation (5.8% vs 4.6%; p=0.030). In multivariable analysis, ranolazine was associated with higher MACE (odds ratio [OR] 2.21; 95% CI 1.44 – 3.30; p<0.001), but was not associated with technical success (OR 1.00; 95% CI 0.82 – 1.22; p>0.9). Patients undergoing CTO PCI who use ranolazine have more comorbidities, more complex lesions, lower technical success, and higher in-hospital MACE.
No takes yet. Share an insight, caveat, or question.
Alexandrou et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: